GLE/PIB in NS5A+SOF failure

Glecaprevir/Pibrentasvir in genotype 1 with failure to NS5A-inhibitor plus sofosbuvir

Sulkowski MS. AASLD 2018, Abs. 0226

Anti-HCV
Glecaprevir (ABT-493)
Pibrentasvir (ABT-530)
Genotype
1
1a
1b
Treatment history
NS5A experienced
SOF-experienced
Cirrhosis
Yes
No

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design


* 5 and ** 1 PI-experienced patients randomized to 12 weeks were treated for 16 weeks and analyzed with 16-W groups

  • GLE/PIB: 100/40 mg 3 tablets QD
  • Weight-based RBV

Objective

  • SVR12 (HCV RNA < LLOQ)
    • Comparison between treatment arms, cirrhosis vs no cirrhosis
    • Comparison between treatment arms, 12 weeks vs 16 weeks treatment durations

Baseline characteristics

SRV12 by treatment arm

  • No virologic failure patients with prior PI therapy (N = 38)

SRV12 by G/P duration and genotype 1 subtype

  • No virologic failure in genotype 1b (N = 34)

Virologic breakthrough (N = 6)

Relapse (N = 7)

Adverse events and laboratory abnormalities